NexImmune, Inc., a biopharmaceutical company, has announced a Special Meeting of Stockholders to be held virtually on July 11, 2024, to vote on the company's dissolution and subsequent liquidation. The meeting follows a series of adjournments due to insufficient quorum and explores the dissolution as the company's efforts to secure additional financing have been unsuccessful. The Board has recommended the liquidation plan, which includes the sale of common stock and warrants for approximately $3.67 million. The Board believes that alternatives to dissolution are limited and may involve seeking voluntary dissolution later with potentially diminished assets or seeking bankruptcy protection. The company has issued a Series A Preferred Stock to ensure the adoption of the dissolution proposal, assuming the majority of common stock votes are in favor. The Board has unanimously recommended stockholders vote for the dissolution and liquidation plan.

NexImmune, Inc., a biopharmaceutical company, has announced a Special Meeting of Stockholders to be held virtually on July 11, 2024, to vote on the company's dissolution and subsequent liquidation. The meeting follows a series of adjournments due to insufficient quorum and explores the dissolution as the company's efforts to secure additional financing have been unsuccessful. The Board has recommended the liquidation plan, which includes the sale of common stock and warrants for approximately $3.67 million. The Board believes that alternatives to dissolution are limited and may involve seeking voluntary dissolution later with potentially diminished assets or seeking bankruptcy protection. The company has issued a Series A Preferred Stock to ensure the adoption of the dissolution proposal, assuming the majority of common stock votes are in favor. The Board has unanimously recommended stockholders vote for the dissolution and liquidation plan.